ITGAX and neoplasm: Utilizing CD11b and CD11c as surface markers to assess the amount of the tumor-infiltrating DCs, we found that MOC2 contained significantly fewer CD11b+CD11c+ cells compared to MOC1 tumors (Figure 1D,E).